PMID- 32369208
OWN - NLM
STAT- MEDLINE
DCOM- 20201229
LR  - 20220716
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Print)
IS  - 0146-6615 (Linking)
VI  - 92
IP  - 10
DP  - 2020 Oct
TI  - Clinical features of patients with coronavirus disease 2019 from a designated 
      hospital in Beijing, China.
PG  - 2055-2066
LID - 10.1002/jmv.25966 [doi]
AB  - Clinical and laboratory data on patients with coronavirus disease 2019 (COVID-19) 
      in Beijing, China, remain extremely limited. In this study, we summarized the 
      clinical characteristics of patients with COVID-19 from a designated hospital in 
      Beijing. In total, 55 patients with laboratory-confirmed SARS-CoV-2 infection in 
      Beijing 302 Hospital were enrolled in this study. Demographic data, symptoms, 
      comorbidities, laboratory values, treatments, and clinical outcomes were all 
      collected and retrospectively analyzed. A total of 15 (27.3%) patients had severe 
      symptoms, the mean age was 44.0 years (interquartile range [IQR], 34.0-56.0), and 
      the median incubation period was 7.5 days (IQR, 5.0-11.8). A total of 26 (47.3%) 
      patients had exposure history in Wuhan of less than 2 weeks, whereas 20 (36.4%) 
      patients were associated with familial clusters. Also, eighteen (32.7%) patients 
      had underlying comorbidities including hypertension. The most common symptom of 
      illness was fever (45; 81.8%); 51 (92.7%) patients had abnormal findings on chest 
      computed tomography. Laboratory findings showed that neutrophil count, percentage 
      of lymphocyte, percentage of eosinophil, eosinophil count, erythrocyte 
      sedimentation rate, albumin, and serum ferritin are potential risk factors for 
      patients with a poor prognosis. A total of 26 patients (47.3%) were still 
      hospitalized, whereas 29 (52.7%) patients had been discharged. Compared with 
      patients in Wuhan, China, the symptoms of patients in Beijing are relatively 
      mild. Older age, more comorbidities, and more abnormal prominent laboratory 
      markers were associated with a severe condition. On the basis of antiviral drugs, 
      it is observed that antibiotics treatment, appropriate dosage of corticosteroid, 
      and gamma globulin therapy significantly improve patients' outcomes. Early 
      identification and timely medical treatment are important to reduce the severity 
      of patients with COVID-19.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Sun, Lijun
AU  - Sun L
AUID- ORCID: 0000-0001-8681-6980
AD  - Research Center for Clinical and Translational Medicine, Beijing 302 Hospital/The 
      Fifth Medical Center of PLA General Hospital, Beijing, China.
FAU - Shen, Lijun
AU  - Shen L
AUID- ORCID: 0000-0002-0347-7432
AD  - The First Liver Cirrhosis Diagnosis and Treatment Center, Beijing 302 
      Hospital/The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 
      China.
FAU - Fan, Junfen
AU  - Fan J
AUID- ORCID: 0000-0003-1892-5768
AD  - Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu 
      Hospital of Capital Medical University, Beijing, China.
FAU - Gu, Fengjun
AU  - Gu F
AUID- ORCID: 0000-0001-5347-307X
AD  - Medical Information Center Department, Beijing 302 Hospital/The Fifth Medical 
      Center of Chinese PLA General Hospital, Beijing, China.
FAU - Hu, Mei
AU  - Hu M
AUID- ORCID: 0000-0002-7363-3891
AD  - Library, Beijing 302 Hospital/The Fifth Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - An, Yiran
AU  - An Y
AUID- ORCID: 0000-0002-7633-2330
AD  - The Medical Center of Clinical Laboratory, Beijing 302 Hospital/the Fifth Medical 
      Center of Chinese PLA General Hospital, Beijing, China.
FAU - Zhou, Qing
AU  - Zhou Q
AUID- ORCID: 0000-0002-0069-559X
AD  - The Medical Center of Clinical Laboratory, Beijing 302 Hospital/the Fifth Medical 
      Center of Chinese PLA General Hospital, Beijing, China.
FAU - Fan, Huahao
AU  - Fan H
AUID- ORCID: 0000-0001-5007-2158
AD  - College of Life Science and Technology, Beijing University of Chemical 
      Technology, Beijing, China.
FAU - Bi, Jingfeng
AU  - Bi J
AUID- ORCID: 0000-0002-4114-4372
AD  - Research Center for Clinical and Translational Medicine, Beijing 302 Hospital/The 
      Fifth Medical Center of PLA General Hospital, Beijing, China.
LA  - eng
GR  - BUCTZY2012/Fundamental Research Funds for Central Universities/International
GR  - 2018ZX09711003-004-003/National Key Research and Development Plan of 
      China/International
GR  - 2019M65072/China Postdoctoral Science Foundation/International
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200612
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antiviral Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 9007-73-2 (Ferritins)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Antiviral Agents/therapeutic use
MH  - COVID-19/diagnostic imaging/*physiopathology/therapy/virology
MH  - China
MH  - Comorbidity
MH  - Coronary Disease/diagnostic imaging/*physiopathology/therapy/virology
MH  - Diabetes Mellitus/diagnostic imaging/*physiopathology/therapy/virology
MH  - Eosinophils/pathology/virology
MH  - Female
MH  - Ferritins/blood
MH  - Fever/physiopathology
MH  - Hospitalization
MH  - Hospitals
MH  - Humans
MH  - Hypertension/diagnostic imaging/*physiopathology/therapy/virology
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Infectious Disease Incubation Period
MH  - Kidney Failure, Chronic/diagnostic imaging/*physiopathology/therapy/virology
MH  - Leukocyte Count
MH  - Lymphocytes/pathology/virology
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/pathology/virology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - SARS-CoV-2/drug effects/pathogenicity
MH  - Severity of Illness Index
MH  - Tomography, X-Ray Computed
PMC - PMC7267635
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - clinical features
OT  - coronavirus disease 2019
OT  - designated Hospital in Beijing
COIS- The authors declare that there are no conflict of interests.
EDAT- 2020/05/06 06:00
MHDA- 2020/12/30 06:00
PMCR- 2020/06/12
CRDT- 2020/05/06 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/04/30 00:00 [revised]
PHST- 2020/05/02 00:00 [accepted]
PHST- 2020/05/06 06:00 [pubmed]
PHST- 2020/12/30 06:00 [medline]
PHST- 2020/05/06 06:00 [entrez]
PHST- 2020/06/12 00:00 [pmc-release]
AID - JMV25966 [pii]
AID - 10.1002/jmv.25966 [doi]
PST - ppublish
SO  - J Med Virol. 2020 Oct;92(10):2055-2066. doi: 10.1002/jmv.25966. Epub 2020 Jun 12.